Advertisement
Advertisement
MGX
Metagenomi Therapeutics, Inc. Common Stock
1.41
USDSponsored
-0.01
-0.70%
May 08, 15:52 UTC -4
Closed
After-Market
1.41
0.00
-0.21%
MGX Earnings Reports
Positive Surprise Ratio
MGX beat 7 of 9 last estimates.
78%
Next Report
Date of Next Report
May 19, 2026
Estimate for Q1 26 (Revenue/ EPS)
$5.98M
/-$0.53
Implied change from Q4 25 (Revenue/ EPS)
+53.01%
/-11.67%
Implied change from Q1 25 (Revenue/ EPS)
+45.00%
/-22.06%
Metagenomi Therapeutics, Inc. Common Stock earnings per share and revenue
On Mar 05, 2026, MGX reported earnings of -0.60 USD per share (EPS) for Q4 25, beating the estimate of -0.61 USD, resulting in a 1.88% surprise. Revenue reached 3.91 million, compared to an expected 6.81 million, with a -42.59% difference. The market reacted with a -8.07% price change (close before vs. close after earnings).
Looking ahead to Q1 26, 3 analysts forecast an EPS of -0.53 USD, with revenue projected to reach 5.98 million USD, implying an decrease of -11.67% EPS, and increase of 53.01% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Taysha Gene Therapies, Inc. Common Stock
Report Date
May 06, 2026 For Q1 26
Estimate
-$0.09
Actual
-$0.12
Surprise
-20.48%
Amphastar Pharmaceuticals, Inc.
Report Date
May 07, 2026 For Q1 26
Estimate
$0.71
Actual
$0.42
Surprise
-41.59%
Personalis, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.27
Actual
-$0.28
Surprise
-5.42%
Teva Pharmaceutical Industries Limited - ADR
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.48
Actual
$0.53
Surprise
+8.78%
BridgeBio Pharma, Inc. Common Stock
Report Date
May 07, 2026 For Q1 26
Estimate
-$0.69
Actual
-$0.84
Surprise
-21.37%
Supernus Pharmaceuticals, Inc.
Report Date
May 05, 2026 For Q1 26
Estimate
$0.30
Actual
$0.59
Surprise
+94.40%
Bausch Health Companies Inc
Report Date
Apr 29, 2026 For Q1 26
Estimate
$0.69
Actual
$0.78
Surprise
+12.33%
FAQ
What were Metagenomi Therapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q4 2025?
For Q4 2025, Metagenomi Therapeutics, Inc. Common Stock reported EPS of -$0.60, beating estimates by 1.88%, and revenue of $3.91M, -42.59% below expectations.
How did the market react to Metagenomi Therapeutics, Inc. Common Stock's Q4 2025 earnings?
The stock price moved down -8.07%, changed from $1.61 before the earnings release to $1.48 the day after.
When is Metagenomi Therapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for May 19, 2026.
What are the forecasts for Metagenomi Therapeutics, Inc. Common Stock's next earnings report?
Based on 3
analysts, Metagenomi Therapeutics, Inc. Common Stock is expected to report EPS of -$0.53 and revenue of $5.98M for Q1 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement